NovaBay Pharmaceuticals, Inc. (NBY) Financials

NBY

Trailing 12 months to March 31, 2026

Revenue Not reported for the trailing 12 months

Net Income Not reported for the trailing 12 months

EPS (Diluted) Not reported for the trailing 12 months

Operating Cash Flow -$8.9M -30.2% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 15, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 15, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NBY SEC filings page.

This page shows NovaBay Pharmaceuticals, Inc. (NBY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NBY FY2025 2026-08-30

NovaBay’s reported economics are constrained less by product margins than by overhead, cash losses, and capital structure.

Gross margin reached 66.3% in FY2024, but operating losses still widened relative to FY2023; overhead absorbed product-level profit rather than weak unit economics explaining the entire shortfall. In FY2025, operating cash flow of -$8.43M nearly matched the operating loss of $8.439M, indicating little accrual-to-cash gap in the reported loss.

Equity moved from positive $3.314M in FY2023 to negative -$129K in FY2024, showing that accumulated losses had consumed the previously positive capital base. The current ratio then moved from short-term balance-sheet pressure at 0.7x in FY2024 to 7.6x in FY2025, a sharp change in reported coverage.

FY2025 financing cash flow was $4.615M while dividends paid were $4.817M, so financing inflow was broadly absorbed by distributions rather than retained for operating needs. The share count rose from 977K shares in FY2024 to 25.2M shares in FY2025, signaling a radically changed capital base.

Financial Health Signals

Financial health score not available

NovaBay Pharmaceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.5M

NovaBay Pharmaceuticals, Inc. generated $2.5M in revenue in Q1 2026.

Net Income

$552.4M

YoY+7102.1%

NovaBay Pharmaceuticals, Inc. reported $552.4M in net income in Q1 2026. This represents an increase of 7102.1% from the same quarter a year earlier.

EPS (Diluted)

$3.33

NovaBay Pharmaceuticals, Inc. earned $3.33 per diluted share (EPS) in Q1 2026.

EBITDA

Not reported for Q1 2026.

Cash & Balance Sheet

Cash & Debt

$18.4M

YoY+117.4%

QoQ+131.3%

5Y CAGR+11.9%

10Y CAGR+29.1%

NovaBay Pharmaceuticals, Inc. held $18.4M in cash against $0 in long-term debt as of Q1 2026.

Shares Outstanding

27M

QoQ+5.6%

5Y CAGR-8.6%

10Y CAGR+18.2%

NovaBay Pharmaceuticals, Inc. had 27M shares outstanding in Q1 2026. Against the prior quarter it is up 5.6%.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Return on Equity

397.9%

YoY+273.5pp

NovaBay Pharmaceuticals, Inc.'s ROE was 397.9% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is up 273.5 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q1 2026.

Operating Margin

Not shown for Q1 2026: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q1 2026: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

None of these metrics is reported for Q1 2026.

NBY Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NBY quarterly income statement

Metric	TTM	FY2510-K	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	N/A	N/A	$9.8M-6.4%	$10.5M-27.4%	$14.4M+41.2%	$10.2M+2.7%	$9.9M+50.5%	$6.6M-47.2%	$12.5M-31.4%	$18.2M+53.2%	$11.9M+171.6%	$4.4M+315.7%	$1.1M-69.7%	$3.5M-49.8%	$6.9M-37.1%	$11.0M
Cost of Revenue	N/A	N/A	$3.3M-24.5%	$4.4M-34.0%	$6.6M+79.5%	$3.7M-7.1%	$4.0M+128.4%	$1.7M+15.6%	$1.5M-46.0%	$2.8M+13.0%	$2.5M+95.4%	$1.3M+159.5%	$486K+200.0%	$162K+1925.0%	$8K	N/A
Gross Profit	N/A	N/A	$6.5M+6.5%	$6.1M-21.8%	$7.8M+19.4%	$6.5M+9.2%	$6.0M+22.7%	$4.9M-55.8%	$11.0M-28.8%	$15.4M+63.7%	$9.4M+202.3%	$3.1M+449.3%	$568K-82.9%	$3.3M+55150.0%	$6K	N/A
R&D Expenses	N/A	N/A	$42K+23.5%	$34K-80.5%	$174K+295.5%	$44K-84.6%	$285K+54.9%	$184K-29.0%	$259K-36.8%	$410K-70.1%	$1.4M-76.1%	$5.7M-39.6%	$9.5M-23.9%	$12.5M+34.4%	$9.3M-6.4%	$9.9M
SG&A Expenses	N/A	$7.6M+2.8%	$7.4M+35.5%	$5.4M-27.3%	$7.5M+3.4%	$7.2M+22.0%	$5.9M+11.7%	$5.3M-8.9%	$5.8M-32.5%	$8.6M+19.4%	$7.2M-60.0%	$18.1M+128.0%	$7.9M+25.2%	$6.3M+6.1%	$6.0M+10.0%	$5.4M
Operating Income	N/A	-$8.4M-14.4%	-$7.4M-79.9%	-$4.1M+71.5%	-$14.4M-62.7%	-$8.9M-37.9%	-$6.4M+31.6%	-$9.4M-19.4%	-$7.9M-7.7%	-$7.3M+33.4%	-$11.0M+48.0%	-$21.1M-25.0%	-$16.9M-9.2%	-$15.5M-86.4%	-$8.3M-92.3%	-$4.3M
EBITDA	N/A	N/A	-$7.2M-77.4%	-$4.1M+71.7%	-$14.3M-62.4%	-$8.8M-38.1%	-$6.4M+31.7%	-$9.3M-22.7%	-$7.6M-5.4%	-$7.2M+33.6%	-$10.9M+48.2%	-$21.0M-25.8%	-$16.7M-9.9%	-$15.2M-90.4%	-$8.0M-104.5%	-$3.9M
Income Tax	N/A	$0	$0	$0	$0	$0-100.0%	$5K-16.7%	$6K+50.0%	$4K+33.3%	$3K+50.0%	$2K0.0%	$2K0.0%	$2K+25.0%	$2K-20.0%	$2K0.0%	$2K
Net Income	N/A	N/A	-$7.2M+25.1%	-$9.6M+9.1%	-$10.6M-82.1%	-$5.8M+47.2%	-$11.0M-14.3%	-$9.7M-47.6%	-$6.5M+11.6%	-$7.4M+43.7%	-$13.2M+30.7%	-$19.0M-24.9%	-$15.2M+5.3%	-$16.0M-128.3%	-$7.0M-38.2%	-$5.1M
EPS (Basic)	N/A	-$108.39-754.8%	-$12.68+90.9%	-$139.14-1277.6%	-$10.10-92.0%	-$5.26-1596.8%	-$0.31+35.4%	-$0.48-23.1%	-$0.39+18.7%	-$0.48+65.7%	-$1.40+79.5%	-$6.82+10.8%	-$7.65+27.2%	-$10.51-4279.2%	-$0.24-20.0%	-$0.20
EPS (Diluted)	—	N/A	N/A	N/A	N/A	N/A	-$0.31	-$0.48-4.3%	-$0.46+4.2%	-$0.48	-$1.40	-$6.82+10.8%	-$7.65+27.2%	-$10.51	-$0.24-20.0%	-$0.20
Diluted Shares (Avg)	N/A	N/A	N/A	N/A	N/A	N/A	35M	22M+26.9%	17M+11.3%	15M	9M	3M+40.3%	2M+30.0%	2M	29M+14.3%	26M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Revenue	$2.5M	N/A	$521K	N/A	$0-100.0%	N/A	$0-100.0%	$2.4M-32.1%
Cost of Revenue	N/A	N/A	$479K	N/A	N/A	N/A	$0-100.0%	$808K-55.0%
Gross Profit	N/A	N/A	$42K	N/A	N/A	N/A	$0-100.0%	$1.6M-8.5%
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	$4K0.0%	$9K-59.1%
SG&A Expenses	$2.8M+5.4%	N/A	$1.2M-28.9%	$1.9M+16.9%	$2.7M+17.9%	N/A	$1.7M+55.8%	$1.6M+1.5%
Operating Income	$22.3M+777.5%	N/A	-$1.3M+26.2%	-$1.9M-16.9%	-$3.3M-43.6%	N/A	-$1.7M-144.0%	-$1.6M-53.9%
EBITDA	N/A	N/A	-$1.3M+26.3%	-$1.9M-17.5%	-$3.3M-44.3%	N/A	-$1.7M-148.5%	-$1.6M-55.0%
Income Tax	$3.5M	N/A	$0	$100K	$0	N/A	$0	$0
Net Income	$552.4M+7102.1%	N/A	-$1.3M-6.7%	-$1.9M-21.3%	$7.7M+338.6%	N/A	-$1.2M+31.0%	-$1.6M+22.2%
EPS (Basic)	$21.23+194.0%	N/A	-$0.22+88.5%	-$0.33+75.9%	$7.22+124.1%	N/A	-$1.92+85.4%	-$1.37+96.9%
EPS (Diluted)	$3.33	N/A	-$0.22	-$0.33	$7.08	N/A	-$1.92	-$1.37
Diluted Shares (Avg)	166M	N/A	6M	6M	1M	N/A	1M	1M

Not reported in any period shown, so not listed: Interest Expense.

NBY Balance Sheet

NBY quarterly balance sheet

Metric	FY2510-K	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$9.0M+163.9%	$3.4M-62.1%	$9.0M-44.9%	$16.4M-31.6%	$24.0M+57.4%	$15.2M+35.8%	$11.2M+19.9%	$9.4M-7.1%	$10.1M-34.5%	$15.4M+203.0%	$5.1M-32.6%	$7.5M-51.8%	$15.7M-18.6%	$19.2M+20.5%	$16.0M
Current Assets	$8.7M+348.3%	$1.9M-73.0%	$7.2M-36.9%	$11.3M-14.0%	$13.2M-7.5%	$14.2M+51.8%	$9.4M+9.0%	$8.6M-4.3%	$9.0M-37.8%	$14.5M+219.7%	$4.5M-34.9%	$7.0M-53.0%	$14.8M-19.1%	$18.3M+25.6%	$14.6M
Cash & Equivalents	$8.0M+1750.7%	$430K-85.3%	$2.9M-45.5%	$5.4M-28.5%	$7.5M-37.2%	$12.0M+72.3%	$6.9M+117.9%	$3.2M-0.5%	$3.2M-66.4%	$9.5M+298.8%	$2.4M-56.1%	$5.4M-48.3%	$10.5M-17.6%	$12.7M+51.1%	$8.4M
Short-Term Investments	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Inventory	N/A	$0-100.0%	$501K-85.4%	$3.4M+6.7%	$3.2M+429.6%	$608K+23.6%	$492K+75.7%	$280K-44.4%	$504K-42.3%	$873K-35.1%	$1.3M+158.2%	$521K+125.5%	$231K+904.3%	$23K	N/A
Accounts Receivable	N/A	N/A	$680K-65.5%	$2.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	$0-100.0%	$348K-92.3%	$4.5M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$640.5M+17932.1%	$3.6M-37.9%	$5.7M-2.1%	$5.8M-57.7%	$13.8M+372.8%	$2.9M-71.5%	$10.2M+132.5%	$4.4M-41.1%	$7.5M-9.6%	$8.3M-18.6%	$10.2M+78.9%	$5.7M-20.3%	$7.1M+37.6%	$5.2M-21.6%	$6.6M
Current Liabilities	$1.1M-59.8%	$2.8M-33.5%	$4.3M+0.5%	$4.3M+23.7%	$3.4M+21.5%	$2.8M-50.2%	$5.7M+47.8%	$3.8M-22.7%	$5.0M+15.2%	$4.3M-6.7%	$4.6M+38.5%	$3.3M-7.8%	$3.6M+14.3%	$3.2M+11.8%	$2.8M
Non-Current Liabilities	$639.4M+90077.4%	$709K-50.8%	$1.4M-9.2%	$1.6M-84.7%	$10.4M+11813.8%	$87K-98.1%	$4.6M+714.3%	$560K-77.7%	$2.5M-36.7%	$4.0M-28.6%	$5.5M+136.4%	$2.3M-33.2%	$3.5M+74.2%	$2.0M-46.8%	$3.8M
Total Equity	-$631.8M-489679.1%	-$129K-103.9%	$3.3M-68.6%	$10.6M+3.8%	$10.2M-17.4%	$12.3M+1166.0%	$973K-80.4%	$5.0M+91.0%	$2.6M-63.5%	$7.1M+239.3%	-$5.1M-375.9%	$1.8M-78.3%	$8.5M-39.4%	$14.0M+50.4%	$9.3M
Retained Earnings	-$819.1M-346.5%	-$183.5M-4.9%	-$174.8M-10.6%	-$158.2M-11.5%	-$141.9M-4.3%	-$136.1M-8.8%	-$125.0M-8.7%	-$115.0M-3.5%	-$111.1M-7.1%	-$103.7M-14.5%	-$90.5M-26.5%	-$71.5M	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Total Assets	$179.7M+1720.7%	$9.0M+163.9%	$3.5M-10.1%	$6.9M+76.1%	$9.9M+84.3%	$3.4M-62.1%	$3.9M-69.8%	$3.9M-75.5%
Current Assets	$19.1M+110.8%	$8.7M+348.3%	$2.9M+27.2%	$6.1M+171.4%	$9.0M+151.7%	$1.9M-73.0%	$2.3M-72.3%	$2.3M-79.9%
Cash & Equivalents	$18.4M+117.4%	$8.0M+1750.7%	$2.3M+197.6%	$5.3M+611.6%	$8.5M+364.5%	$430K-85.3%	$776K-77.6%	$751K-83.0%
Inventory	N/A	N/A	N/A	$467K-33.3%	N/A	$0-100.0%	$473K-86.5%	$700K-80.9%
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	$704K	$547K
Total Liabilities	$40.9M+1004.4%	$640.5M+17932.1%	$1.9M-33.9%	$2.7M-41.3%	$3.7M-28.7%	$3.6M-37.9%	$2.8M-51.8%	$4.5M-39.0%
Current Liabilities	$3.6M+16.6%	$1.1M-59.8%	$1.4M-27.0%	$2.1M-40.6%	$3.1M-21.8%	$2.8M-33.5%	$2.0M-56.6%	$3.6M-40.5%
Non-Current Liabilities	$37.3M+5753.0%	$639.4M+90077.4%	$405K-50.7%	$522K-44.0%	$638K-49.9%	$709K-50.8%	$821K-34.0%	$932K-32.4%
Long-Term Debt	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$138.8M+2151.1%	-$631.8M-489679.1%	$1.1M+3.5%	$4.2M+788.0%	$6.2M+3754.4%	-$129K-103.9%	$1.1M-84.8%	-$617K-107.2%
Retained Earnings	-$266.7M-51.7%	-$819.1M-346.5%	-$183.8M-0.9%	-$177.7M+1.3%	-$175.8M+1.5%	-$183.5M-4.9%	-$182.2M-10.0%	-$180.0M-9.8%

Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill.

NBY Cash Flow Statement

NBY quarterly cash flow statement

Metric	TTM	FY2510-K	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$8.9M	-$8.4M-12.4%	-$7.5M-81.5%	-$4.1M+37.9%	-$6.7M+27.6%	-$9.2M-94.7%	-$4.7M+40.5%	-$7.9M-42.4%	-$5.6M+11.2%	-$6.3M+46.2%	-$11.7M+37.2%	-$18.6M-23.3%	-$15.1M-16.1%	-$13.0M-98.7%	-$6.5M-107.8%	-$3.1M
Depreciation & Amortization	N/A	N/A	$192K+276.5%	$51K-57.5%	$120K+103.4%	$59K+15.7%	$51K-21.5%	$65K-75.6%	$266K+180.0%	$95K-16.7%	$114K-30.5%	$164K-29.3%	$232K-26.1%	$314K-7.9%	$341K-19.8%	$425K
Stock-Based Compensation	N/A	$29K-80.4%	$148K-49.1%	$291K+32.3%	$220K-76.4%	$933K+75.4%	$532K+9.5%	$486K-27.6%	$671K-73.6%	$2.5M+45.2%	$1.8M+46.6%	$1.2M+40.0%	$853K-7.4%	$921K-29.0%	$1.3M+16.8%	$1.1M
Capital Expenditures	N/A	N/A	$6K-68.4%	$19K-83.0%	$112K+115.4%	$52K+100.0%	$26K+36.8%	$19K-56.8%	$44K-82.0%	$244K+52.5%	$160K+30.1%	$123K+80.9%	$68K-51.8%	$141K-4.7%	$148K+24.4%	$119K
Free Cash Flow	N/A	N/A	-$7.5M-80.8%	-$4.2M+38.7%	-$6.8M+26.8%	-$9.2M-94.7%	-$4.7M+40.3%	-$7.9M-41.6%	-$5.6M+13.8%	-$6.5M+44.9%	-$11.8M+36.7%	-$18.7M-23.5%	-$15.1M-15.4%	-$13.1M-96.4%	-$6.7M-104.7%	-$3.3M
Investing Cash Flow	N/A	N/A	$1.1M+5700.0%	-$19K+83.0%	-$112K+99.1%	-$12.0M-46226.9%	-$26K-36.8%	-$19K+56.8%	-$44K+82.0%	-$244K-52.5%	-$160K-86.0%	-$86K-103.3%	$2.6M+84.6%	$1.4M+3.2%	$1.4M+129.2%	-$4.7M
Financing Cash Flow	$44.7M	$4.6M+207.9%	$1.5M-21.5%	$1.9M-58.8%	$4.6M-72.4%	$16.8M+72.0%	$9.8M-16.6%	$11.7M+109.1%	$5.6M+2684.6%	$201K-99.0%	$19.4M+24.5%	$15.6M+111.2%	$7.4M-20.8%	$9.3M-1.5%	$9.5M+101.5%	$4.7M
Dividends Paid	N/A	$4.8M	$0	N/A	N/A	N/A	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Operating Cash Flow	-$1.8M-36.3%	-$2.3M-35.7%	-$1.8M+24.7%	-$3.0M-113.6%	-$1.3M+33.1%	-$1.7M-183.1%	-$2.4M-278.0%	-$1.4M+17.9%
Depreciation & Amortization	N/A	N/A	$1K0.0%	$1K-87.5%	$2K-83.3%	N/A	$1K-92.3%	$8K-38.5%
Stock-Based Compensation	$0	N/A	N/A	N/A	N/A	N/A	$22K-64.5%	$55K-14.1%
Capital Expenditures	N/A	N/A	$0	$0	$0-100.0%	$4K+33.3%	$0-100.0%	$0-100.0%
Free Cash Flow	N/A	N/A	-$1.8M+24.7%	-$3.0M-113.6%	-$1.3M+33.2%	-$1.7M-182.4%	-$2.4M-277.4%	-$1.4M+18.0%
Investing Cash Flow	-$25.9M	N/A	$0	$0	$0+100.0%	$1.1M+35633.3%	$0+100.0%	$0+100.0%
Financing Cash Flow	$38.3M+2344.6%	$7.8M+1463.2%	-$1.3M-163.2%	-$174K+64.6%	-$1.7M-186.1%	$500K+2023.1%	$2.1M+461.9%	-$492K-119.6%
Dividends Paid	N/A	$17K	$4.8M	N/A	N/A	$0	N/A	N/A

Not reported in any period shown, so not listed: Share Buybacks.

NBY Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NBY quarterly financial ratios

Metric	FY2510-K	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	N/A	66.3%+8.1pp	58.2%+4.2pp	54.0%-9.8pp	63.8%+3.8pp	60.0%-13.6pp	73.7%-14.3pp	88.0%+3.2pp	84.7%+5.4pp	79.3%+8.1pp	71.2%+17.3pp	53.9%-41.4pp	95.3%+95.3pp	0.1%	N/A
Operating Margin	N/A	-75.4%-36.2pp	-39.2%	-100.1%	-86.9%-22.2pp	-64.7%	-142.5%	-62.9%-22.8pp	-40.1%+52.2pp	-92.3%	-482.5%	-1603.8%	-445.4%	-119.8%	-39.2%
Net Margin	N/A	-73.9%+18.4pp	-92.2%-18.6pp	-73.7%-16.6pp	-57.1%	-111.1%	-146.4%	-52.3%-11.7pp	-40.6%	-110.5%	-433.1%	-1441.6%	-461.4%	-101.4%	-46.2%
Return on Equity	N/A	N/A	-290.9%-190.4pp	-100.5%-43.3pp	-57.3%+32.4pp	-89.6%+903.0pp	-992.6%-860.5pp	-132.1%+153.3pp	-285.4%-100.2pp	-185.2%	N/A	-822.2%-633.8pp	-188.4%-138.3pp	-50.0%+4.4pp	-54.4%
Return on Assets	N/A	-211.0%-104.3pp	-106.7%-42.0pp	-64.7%-40.4pp	-24.3%+48.2pp	-72.4%+13.6pp	-86.1%-16.2pp	-69.9%+3.5pp	-73.5%+12.0pp	-85.5%+288.2pp	-373.7%-172.1pp	-201.6%-99.1pp	-102.5%-66.0pp	-36.5%-4.7pp	-31.9%
Current Ratio	7.60+6.9x	0.68-1.0x	1.67-1.0x	2.66-1.2x	3.83-1.2x	5.03+3.4x	1.65-0.6x	2.24+0.4x	1.81-1.5x	3.35+2.4x	0.98-1.1x	2.08-2.0x	4.08-1.7x	5.76+0.6x	5.13
Debt-to-Equity	N/A	N/A	1.73+1.2x	0.55-0.8x	1.36+1.1x	0.24-10.3x	10.53+9.6x	0.89-2.0x	2.89+1.7x	1.17	N/A	3.08+2.2x	0.84+0.5x	0.37-0.3x	0.71
Asset Turnover	N/A	2.86+1.7x	1.16+0.3x	0.88+0.5x	0.43-0.2x	0.65+0.1x	0.59-0.7x	1.34-0.5x	1.81+1.0x	0.77-0.1x	0.86+0.7x	0.14-0.1x	0.22-0.1x	0.36-0.3x	0.69
FCF Margin	N/A	-76.7%-37.0pp	-39.7%+7.3pp	-47.0%+43.6pp	-90.6%-42.8pp	-47.8%	-120.4%	-44.9%-9.1pp	-35.7%+63.6pp	-99.4%	-426.4%	-1434.8%	-377.1%	-96.3%-66.7pp	-29.6%

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Gross Margin	N/A	N/A	8.1%	N/A	N/A	N/A	N/A	66.3%+17.1pp
Operating Margin	905.0%	N/A	-241.1%	N/A	N/A	N/A	N/A	-67.4%-37.6pp
Net Margin	22428.1%	N/A	-248.2%	N/A	N/A	N/A	N/A	-66.0%-8.4pp
Return on Equity	397.9%+273.5pp	N/A	-116.6%-3.5pp	-45.3%	124.4%+2133.1pp	N/A	-113.1%-88.1pp	N/A
Return on Assets	307.3%+229.6pp	N/A	-37.1%-5.8pp	-27.8%+12.6pp	77.7%+137.7pp	N/A	-31.3%-17.6pp	-40.4%-27.7pp
Current Ratio	5.33+2.4x	7.60+6.9x	2.00+0.9x	2.85+2.2x	2.95+2.0x	0.68-1.0x	1.15-0.6x	0.62-1.2x
Debt-to-Equity	0.29-0.3x	N/A	1.67-0.9x	0.63	0.60-31.9x	N/A	2.62+1.8x	N/A
Asset Turnover	0.010.0x	N/A	0.15+0.1x	N/A	0.00-0.5x	N/A	0.00-0.2x	0.61+0.4x
FCF Margin	N/A	N/A	-353.2%	N/A	N/A	N/A	N/A	-58.3%-10.0pp

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$631.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
NovaBay Pharmaceuticals, Inc. NBY	FY2025	N/A	N/A	N/A	$51.9M	—
Edesa Biotech, Inc. EDSA	FY2025	N/A	-$7.2M	N/A	$38.7M	—
MetaVia Inc. MTVA	FY2025	N/A	-$13.0M	N/A	$10.1M	—
Portage Biotech Inc. PRTG	FY2018	N/A	$123.7M	N/A	$15.5M	—
Pulmatrix, Inc. PULM	FY2025	N/A	-$5.2M	N/A	$5.6M	—
SYNLOGIC INC SYBX	FY2025	$0	-$1.0M	N/A	$6.6M	—

Where NovaBay Pharmaceuticals, Inc. Ranks

Frequently Asked Questions

Does NovaBay Pharmaceuticals, Inc. pay dividends?

Yes, NovaBay Pharmaceuticals, Inc. (NBY) paid $4.00 per share in dividends during fiscal year 2025.

What is NovaBay Pharmaceuticals, Inc.'s operating cash flow?

NovaBay Pharmaceuticals, Inc. (NBY) recorded an outflow of $8.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are NovaBay Pharmaceuticals, Inc.'s total assets?

NovaBay Pharmaceuticals, Inc. (NBY) had $9.0M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does NovaBay Pharmaceuticals, Inc. have outstanding?

NovaBay Pharmaceuticals, Inc. (NBY) had 25M shares outstanding as of fiscal year 2025.

What is NovaBay Pharmaceuticals, Inc.'s current ratio?

NovaBay Pharmaceuticals, Inc. (NBY) had a current ratio of 7.60 as of fiscal year 2025, which is generally considered healthy.

How does NovaBay Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, NovaBay Pharmaceuticals, Inc. (NBY) held $8.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.4M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is NovaBay Pharmaceuticals, Inc.'s debt-to-equity ratio negative or not reported?

NovaBay Pharmaceuticals, Inc. (NBY) has negative shareholder equity of -$631.8M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.